<p><strong>Aytu BioPharma, Inc.</strong> (NASDAQ:AYTU) 的股票在经历了一段动荡期后，最近一个月表现非常出色，涨幅达 28%。回顾更长时间，令人鼓舞的是，该股票在过去一年中上涨了 85%。</p>
<p>即使在如此大幅的价格跳升之后，考虑到美国制药行业几乎一半的公司市销率（&#34;P/S&#34;）超过 4.3 倍，甚至有些超过 25 倍，Aytu BioPharma 目前仍可能被视为一个强劲的买入机会，其市销率为 0.4 倍。不过，仅仅根据市销率来判断并不明智，因为可能有解释说明其如此低的原因。</p>
<p>这项技术可能会取代计算机：发现 20 只正在努力使量子计算成为现实的股票。</p>
<p>查看我们对 Aytu BioPharma 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/291629081-ps-multiple-vs-industry-1-dark-2/1766237641895?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/291629081-ps-multiple-vs-industry-1-dark-2/1766237641895"/></p>
<p>NasdaqCM:AYTU 市销率与行业比较 2025 年 12 月 20 日</p>
<h3>Aytu BioPharma 最近的表现如何？</h3>
<p>Aytu BioPharma 最近的表现不佳，其收入下降与其他公司相比显得相形见绌，后者的收入平均有所增长。似乎许多人预期收入表现不佳将持续，这抑制了市销率。如果你仍然喜欢这家公司，你会希望这种情况并非如此，以便在它不受欢迎时能够买入一些股票。</p>
<p>如果你想了解分析师对未来的预测，可以查看我们对 Aytu BioPharma 的 <strong>免费</strong> 报告。</p>
<h2>Aytu BioPharma 是否有收入增长的预测？</h2>
<p>为了证明其市销率的合理性，Aytu BioPharma 需要实现微弱的增长，且增长幅度显著低于行业水平。</p>
<p>回顾过去一年，该公司的收入几乎与前一年持平。这并不是股东所期待的，因为这意味着他们在过去三年中总共经历了 38% 的收入下降。因此，可以公平地说，最近的收入增长对公司来说并不理想。</p>
<p>展望未来，覆盖该公司的三位分析师的估计表明，收入增长将进入负增长领域，预计在未来一年下降 2.9%。这并不理想，而行业其他部分预计将增长 25%。</p>
<p>鉴于此，Aytu BioPharma 的市销率低于大多数其他公司是可以理解的。然而，收入的萎缩不太可能在长期内导致稳定的市销率。即使只是维持这些价格，在疲软的前景下也可能难以实现。</p>
<h2>我们可以从 Aytu BioPharma 的市销率中学到什么？</h2>
<p>即使在如此强劲的价格波动之后，Aytu BioPharma 的市销率仍然落后于行业其他公司。通常情况下，我们会警惕在做出投资决策时过度解读市销率，尽管它可以揭示其他市场参与者对公司的看法。</p>
<p>显然，Aytu BioPharma 因其收入下滑的预测而维持低市销率。在这一阶段，投资者认为收入改善的潜力不足以证明更高的市销率。在这种情况下，很难看到股价在不久的将来强劲上涨。</p>
<p>还有其他重要的风险因素需要考虑，我们发现了 <strong>Aytu BioPharma 的 3 个警示信号</strong>（其中 1 个让我们有些不安！），在投资之前你应该了解这些。</p>
<p>如果这些 <strong>风险让你重新考虑对 Aytu BioPharma 的看法</strong>，可以探索我们互动的高质量股票列表，以了解还有什么其他选择。</p>
<p>用于国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随处可用。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

AYTU

<p>Aytu BioPharma, Inc.（纳斯达克代码：AYTU）的股票最近上涨了 28%，在过去一年中上涨了 85%。尽管如此，其市销率为 0.4 倍，低于行业平均水平。该公司的收入在三年内下降了 38%，分析师预测明年的收入将下降 2.9%，而行业则预计增长 25%。这种疲软的前景使其市销率保持在低位，暗示股价增长的潜力有限</p>

<p><strong>Aytu BioPharma, Inc.</strong> (NASDAQ:AYTU) shares have had a really impressive month, gaining 28% after a shaky period beforehand. Looking back a bit further, it's encouraging to see the stock is up 85% in the last year.</p>
<div class="lb-trans"><p><strong>Aytu BioPharma, Inc.</strong> (NASDAQ:AYTU) 的股票在经历了一段动荡期后，最近一个月表现非常出色，涨幅达 28%。回顾更长时间，令人鼓舞的是，该股票在过去一年中上涨了 85%。</p>
</div><p>Even after such a large jump in price, Aytu BioPharma may still look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 0.4x, considering almost half of all companies in the Pharmaceuticals industry in the United States have P/S ratios greater than 4.3x and even P/S higher than 25x aren't out of the ordinary. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited.</p>
<div class="lb-trans"><p>即使在如此大幅的价格跳升之后，考虑到美国制药行业几乎一半的公司市销率（&#34;P/S&#34;）超过 4.3 倍，甚至有些超过 25 倍，Aytu BioPharma 目前仍可能被视为一个强劲的买入机会，其市销率为 0.4 倍。不过，仅仅根据市销率来判断并不明智，因为可能有解释说明其如此低的原因。</p>
</div><p>This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.</p>
<div class="lb-trans"><p>这项技术可能会取代计算机：发现 20 只正在努力使量子计算成为现实的股票。</p>
</div><p>Check out our latest analysis for Aytu BioPharma</p>
<div class="lb-trans"><p>查看我们对 Aytu BioPharma 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/291629081-ps-multiple-vs-industry-1-dark-2/1766237641895" alt="" original-src="https://images.simplywall.st/asset/chart/291629081-ps-multiple-vs-industry-1-dark-2/1766237641895"/></p>
<p>NasdaqCM:AYTU Price to Sales Ratio vs Industry December 20th 2025</p>
<div class="lb-trans"><p>NasdaqCM:AYTU 市销率与行业比较 2025 年 12 月 20 日</p>
</div><h3>How Has Aytu BioPharma Performed Recently?</h3>
<div class="lb-trans"><h3>Aytu BioPharma 最近的表现如何？</h3>
</div><p>Aytu BioPharma hasn't been tracking well recently as its declining revenue compares poorly to other companies, which have seen some growth in their revenues on average. It seems that many are expecting the poor revenue performance to persist, which has repressed the P/S ratio. If you still like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>Aytu BioPharma 最近的表现不佳，其收入下降与其他公司相比显得相形见绌，后者的收入平均有所增长。似乎许多人预期收入表现不佳将持续，这抑制了市销率。如果你仍然喜欢这家公司，你会希望这种情况并非如此，以便在它不受欢迎时能够买入一些股票。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on Aytu BioPharma.</p>
<div class="lb-trans"><p>如果你想了解分析师对未来的预测，可以查看我们对 Aytu BioPharma 的 <strong>免费</strong> 报告。</p>
</div><h2>Is There Any Revenue Growth Forecasted For Aytu BioPharma?</h2>
<div class="lb-trans"><h2>Aytu BioPharma 是否有收入增长的预测？</h2>
</div><p>In order to justify its P/S ratio, Aytu BioPharma would need to produce anemic growth that's substantially trailing the industry.</p>
<div class="lb-trans"><p>为了证明其市销率的合理性，Aytu BioPharma 需要实现微弱的增长，且增长幅度显著低于行业水平。</p>
</div><p>Retrospectively, the last year delivered virtually the same number to the company's top line as the year before. This isn't what shareholders were looking for as it means they've been left with a 38% decline in revenue over the last three years in total. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.</p>
<div class="lb-trans"><p>回顾过去一年，该公司的收入几乎与前一年持平。这并不是股东所期待的，因为这意味着他们在过去三年中总共经历了 38% 的收入下降。因此，可以公平地说，最近的收入增长对公司来说并不理想。</p>
</div><p>Shifting to the future, estimates from the three analysts covering the company suggest revenue growth is heading into negative territory, declining 2.9% over the next year. That's not great when the rest of the industry is expected to grow by 25%.</p>
<div class="lb-trans"><p>展望未来，覆盖该公司的三位分析师的估计表明，收入增长将进入负增长领域，预计在未来一年下降 2.9%。这并不理想，而行业其他部分预计将增长 25%。</p>
</div><p>In light of this, it's understandable that Aytu BioPharma's P/S would sit below the majority of other companies. However, shrinking revenues are unlikely to lead to a stable P/S over the longer term. Even just maintaining these prices could be difficult to achieve as the weak outlook is weighing down the shares.</p>
<div class="lb-trans"><p>鉴于此，Aytu BioPharma 的市销率低于大多数其他公司是可以理解的。然而，收入的萎缩不太可能在长期内导致稳定的市销率。即使只是维持这些价格，在疲软的前景下也可能难以实现。</p>
</div><h2>What We Can Learn From Aytu BioPharma's P/S?</h2>
<div class="lb-trans"><h2>我们可以从 Aytu BioPharma 的市销率中学到什么？</h2>
</div><p>Even after such a strong price move, Aytu BioPharma's P/S still trails the rest of the industry. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.</p>
<div class="lb-trans"><p>即使在如此强劲的价格波动之后，Aytu BioPharma 的市销率仍然落后于行业其他公司。通常情况下，我们会警惕在做出投资决策时过度解读市销率，尽管它可以揭示其他市场参与者对公司的看法。</p>
</div><p>It's clear to see that Aytu BioPharma maintains its low P/S on the weakness of its forecast for sliding revenue, as expected. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. It's hard to see the share price rising strongly in the near future under these circumstances.</p>
<div class="lb-trans"><p>显然，Aytu BioPharma 因其收入下滑的预测而维持低市销率。在这一阶段，投资者认为收入改善的潜力不足以证明更高的市销率。在这种情况下，很难看到股价在不久的将来强劲上涨。</p>
</div><p>There are also other vital risk factors to consider and we've discovered <strong>3 warning signs for Aytu BioPharma</strong> (1 makes us a bit uncomfortable!) that you should be aware of before investing here.</p>
<div class="lb-trans"><p>还有其他重要的风险因素需要考虑，我们发现了 <strong>Aytu BioPharma 的 3 个警示信号</strong>（其中 1 个让我们有些不安！），在投资之前你应该了解这些。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on Aytu BioPharma</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果这些 <strong>风险让你重新考虑对 Aytu BioPharma 的看法</strong>，可以探索我们互动的高质量股票列表，以了解还有什么其他选择。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用于国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随处可用。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

Aytu BioPharma, Inc. (NASDAQ:AYTU) 的股票上涨了 28%，但其股价和业务表现仍然落后于行业水平